Literature DB >> 21727198

1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer.

R Stahel1, N Thatcher2, M Früh3, C Le Péchoux4, P E Postmus5, J B Sorensen6, E Felip7.   

Abstract

The 1st ESMO Consensus Conference on lung cancer was held in Lugano, Switzerland on 21st and 22nd May 2010 with the participation of a multidisciplinary panel of leading professionals in pathology and molecular diagnostics and medical, surgical and radiation oncology. Before the conference, the expert panel prepared clinically relevant questions concerning five areas as follows: early and locally advanced non-small-cell lung cancer (NSCLC), first-line metastatic NSCLC, second-/third-line NSCLC, NSCLC pathology and molecular testing, and small-cell lung cancer (SCLC) to be addressed through discussion at the Consensus Conference. All relevant scientific literature for each question was reviewed in advance. During the Consensus Conference, the panel developed recommendations for each specific question. The consensus agreement in SCLC is reported in this article. The recommendations detailed here are based on an expert consensus after careful review of published data. All participants have approved this final update.

Entities:  

Mesh:

Year:  2011        PMID: 21727198     DOI: 10.1093/annonc/mdr313

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  10 in total

Review 1.  Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.

Authors:  D De Ruysscher; B Lueza; C Le Péchoux; D H Johnson; M O'Brien; N Murray; S Spiro; X Wang; M Takada; B Lebeau; W Blackstock; D Skarlos; P Baas; H Choy; A Price; L Seymour; R Arriagada; J-P Pignon
Journal:  Ann Oncol       Date:  2016-07-19       Impact factor: 32.976

2.  Chemotherapy of lung cancer: A global perspective of the role of ifosfamide.

Authors:  Caicun Zhou; Christian Manegold
Journal:  Transl Lung Cancer Res       Date:  2012-03

3.  The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma.

Authors:  Wei Li; Alexa Cohen; Yin Sun; Jill Squires; Daniel Braas; Thomas G Graeber; Lin Du; Gang Li; Zhen Li; Xiang Xu; Xufeng Chen; Jiaoti Huang
Journal:  Mol Cancer Res       Date:  2016-02-01       Impact factor: 5.852

4.  Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort.

Authors:  Farkhad Manapov; Chukwuka Eze; Maximilian Niyazi; Olarn Roengvoraphoj; Minglun Li; Nina-Sophie Hegemann; Guido Hildebrandt; Rainer Fietkau; Claus Belka
Journal:  J Cancer       Date:  2016-10-17       Impact factor: 4.207

5.  TRIB2 contributes to cisplatin resistance in small cell lung cancer.

Authors:  Yuanxin Liang; Dong Yu; Roman Perez-Soler; Jim Klostergaard; Yiyu Zou
Journal:  Oncotarget       Date:  2017-11-27

6.  Prediction of radiation pneumonitis using dose-volume histogram parameters with high attenuation in two types of cancer: A retrospective study.

Authors:  Yasuki Uchida; Takuya Tsugawa; Sachiko Tanaka-Mizuno; Kazuo Noma; Ken Aoki; Kentaro Fukunaga; Hiroaki Nakagawa; Daisuke Kinose; Masafumi Yamaguchi; Makoto Osawa; Taishi Nagao; Emiko Ogawa; Yasutaka Nakano
Journal:  PLoS One       Date:  2020-12-28       Impact factor: 3.240

Review 7.  Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.

Authors:  Koichi Ando; Ryo Manabe; Yasunari Kishino; Sojiro Kusumoto; Toshimitsu Yamaoka; Akihiko Tanaka; Tohru Ohmori; Tsukasa Ohnishi; Hironori Sagara
Journal:  Curr Oncol       Date:  2021-02-27       Impact factor: 3.677

8.  Consolidative Thoracic Radiation Therapy After First-Line Chemotherapy and Immunotherapy in Extensive-Stage Small Cell Lung Cancer: A Multi-Institutional Case Series.

Authors:  Brett H Diamond; Nipun Verma; Utkarsh C Shukla; Henry S Park; Paul P Koffer
Journal:  Adv Radiat Oncol       Date:  2021-12-24

9.  Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis.

Authors:  Dongliang Bian; Siming Jiang; Yicheng Xiong; Mengfan Qi; Jiawei Wu; Alfredo Addeo; Yoshikane Yamauchi; Farkhad Manapov; Wolfram C M Dempke; Jacopo Vannucci; Alessandro Di Federico; Xiaoxiong Xu; Linsong Chen
Journal:  Transl Lung Cancer Res       Date:  2022-08

10.  Survival Outcomes for Patients with Surgical and Non-Surgical Treatments in Stages I-III Small-Cell Lung Cancer.

Authors:  Keying Che; Hongchang Shen; Xiao Qu; Zhaofei Pang; Yuanzhu Jiang; Shaorui Liu; Xudong Yang; Jiajun Du
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.